Express News | Telomir Pharmaceuticals Announced It Raised $1M In Equity Funding Through Starwood Trust
Telomir Pharmaceuticals Enters Into Stock Purchase Agreement
Telomir Pharmaceuticals Raises $1M At $7 Per Share In No-warrant, Restricted Common Stock Deal - Filing
Individual Investors Are Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) Biggest Owners and Were Rewarded After Market Cap Rose by US$75m Last Week
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
Sector Update: Health Care Stocks Climb Thursday Afternoon
Sector Update: Health Care
Telomir Pharmaceuticals Shares Are Trading Higher After the Company Announced Preclinical Results Confirming the Efficacy of Telomir-1.
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study With Telomir-1
Telomir Pharma Shares Rise 4% After Anti-Aging Drug News
Telomir Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Telomir Pharmaceuticals Special Advisor Dr. Michael Roizen to Discuss Telomir-1 and the Science of Longevity on Health Uncensored With Dr. Drew on the Fox Business Network This Sunday
Telomir Pharmaceuticals Reaches US$198m Market Cap Benefiting Insider Stock Buying
Telomir Pharmaceuticals Insider Ups Holding During Year
Telomir Pharmaceuticals Appoints Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo (Now Sanofi-Aventis), to Lead IND and INAD Applications for Human and Veterinary Indications
Telomir Pharmaceuticals Featured in Local ABC Exclusive Showing Positive Outcomes of Proposed Age Reversal Pill in Dogs
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Telomir Pharmaceuticals | 10-Q: Q2 2024 Earnings Report
Telomir Pharma: Hugh McColl III, Talhia Tuck and Brad Kroenig Resign From the Board>TELO
Telomir Pharma Names Matthew P. Del Giudice, Ned MacPherson and Matthew Pratt Whalen to Board >TELO